Note J - Patents

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Text Block]

NOTE

J — PATENTS

	2017				2016
	Cost	Accumulated Amortization		Net	Cost	Accumulated Amortization		Net
Patents-foundation intellectual property	1,377,863	(787,821	)	590,042	1,377,543	(717,086	)	660,457
Epidural-Apad acquired patents	2,639,647	(439,941	)	2,199,706	-	-		-
Total	4,017,510	(1,227,762	)	2,789,748	1,377,543	(717,086	)	660,457

Patents are amortized utilizing the straight-line method over estimated useful lives ranging from

years, with a weighted average amortization period of

years. Amortization expense was

$510,676

and

$70,699

for the year ended

December 31, 2017

and

2016,

respectively. The annual amortization expense expected to be recorded for existing intangibles assets for the years

2018

through

2022

$945,000,

$932,000,

$486,000,

$39,000

and

$38,000.

July 13, 2017,

Milestone Scientific consummated a previously disclosed Asset Purchase Agreement (the “Agreement”) with APAD Octrooi B.V. and APAD B.V. (each, a “Seller” and collectively, the “Sellers”) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers’ computer-controlled injection instrument (the “Purchased Assets”) and has been accounted for as an asset acquisition. On the closing date, Milestone Scientific issued to the Sellers an aggregate of

1,646,358

shares of its common stock, valued at approximately

$2,486,000

for the Purchased Assets which shares are subject to certain post-closing upward or downward adjustments

not

to exceed

twenty-five

percent of the initial shares as of the purchase date or

250,000

Euros, as defined in the agreement. As of

December 31, 2017,

Milestone Scientific has recorded a

$275,000

liability relating to the estimated additional shares that would have to be issued according this provision in the Agreement. Milestone Scientific paid approximately

$153,000

in legal fees on behalf of the Seller as stipulated based on the terms of the Agreement. The patents purchased in the amount of approximately

$2,639,000

have been capitalized and will amortized over their

three

-year estimated useful life and tested for impairment as a finite lived intangible asset.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details